WO2005092374A3 - Virus d'herpes simplex recombinant et leurs utilisations - Google Patents

Virus d'herpes simplex recombinant et leurs utilisations Download PDF

Info

Publication number
WO2005092374A3
WO2005092374A3 PCT/EP2005/003639 EP2005003639W WO2005092374A3 WO 2005092374 A3 WO2005092374 A3 WO 2005092374A3 EP 2005003639 W EP2005003639 W EP 2005003639W WO 2005092374 A3 WO2005092374 A3 WO 2005092374A3
Authority
WO
WIPO (PCT)
Prior art keywords
hsv
vaccine
herpes simplex
simplex virus
recombinant herpes
Prior art date
Application number
PCT/EP2005/003639
Other languages
English (en)
Other versions
WO2005092374A2 (fr
Inventor
Barbara Ensoli
Antonella Caputo
Peggy Marconi
Original Assignee
Ist Superiore Sanita
Barbara Ensoli
Antonella Caputo
Peggy Marconi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ist Superiore Sanita, Barbara Ensoli, Antonella Caputo, Peggy Marconi filed Critical Ist Superiore Sanita
Publication of WO2005092374A2 publication Critical patent/WO2005092374A2/fr
Publication of WO2005092374A3 publication Critical patent/WO2005092374A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention a trait à un HSV à réplication déficiente codant pour un antigène hétérologue, et à un vaccin comportant le HSV. Le vaccin peut être dirigé contre des virus, des bactéries intracellulaires ou des tumeurs. L'invention a également trait à un vaccin anticancéreux comportant un HSV à réplication déficiente codant pour un inhibiteur de l'angiogenèse, une cytokine et un gène suicide. L'invention a trait en outre à un modèle de provocation pour le criblage d'antigènes candidats, tel qu'un vecteur HSV mutant UL13. L'invention a trait en outre à des vecteurs de HSV pour l'expression de Hex A et des NTF, et à des procédés comprenant ledit HSV.
PCT/EP2005/003639 2004-03-22 2005-03-22 Virus d'herpes simplex recombinant et leurs utilisations WO2005092374A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0406389.7 2004-03-22
GBGB0406389.7A GB0406389D0 (en) 2004-03-22 2004-03-22 Recombinant herpes simplex virus and uses therefor

Publications (2)

Publication Number Publication Date
WO2005092374A2 WO2005092374A2 (fr) 2005-10-06
WO2005092374A3 true WO2005092374A3 (fr) 2005-12-08

Family

ID=32118151

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/003639 WO2005092374A2 (fr) 2004-03-22 2005-03-22 Virus d'herpes simplex recombinant et leurs utilisations

Country Status (2)

Country Link
GB (1) GB0406389D0 (fr)
WO (1) WO2005092374A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2317749B1 (es) * 2006-07-20 2010-02-19 Consejo Superior Investig. Cientificas Uso de un compuesto proteico derivado de la glicoproteina (gg) de hsv para la elaboracion de una composicion farmaceutica util para la induccion de migracion celular mediada por quimioquinas.
US20110110892A1 (en) * 2008-03-24 2011-05-12 President And Fellows Of Harvard College Vectors for delivering disease neutralizing agents
US8637046B2 (en) 2008-10-03 2014-01-28 Cornell University Bovine herpes virus-1 compositions, vaccines and methods
GB201301119D0 (en) * 2013-01-22 2013-03-06 Vaxxit Srl Viral vaccines
WO2015123307A1 (fr) * 2014-02-11 2015-08-20 University Of Miami Procédés et compositions pour l'expression d'un transgène dans un système de vecteur du virus de l'herpès
PT3408382T (pt) 2016-01-27 2022-06-27 Oncorus Inc Vetores virais oncolíticos e seus usos
CN116064423A (zh) * 2016-03-25 2023-05-05 普瑞菲根公司 用于递送nt3和治疗cipn的hsv载体
US11753653B2 (en) * 2016-03-25 2023-09-12 Periphagen, Inc. High-transducing HSV vectors
CA3070299A1 (fr) 2017-07-26 2019-01-31 Oncorus, Inc. Vecteurs viraux oncolytiques et leurs utilisations
CN112656798B (zh) * 2020-12-28 2023-03-07 复旦大学附属肿瘤医院 Cdk7靶向抑制剂在制备治疗细胞因子释放综合征药物中的应用
CN117412986A (zh) * 2021-04-02 2024-01-16 克里斯托生物技术股份有限公司 用于癌症疗法的病毒载体

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6423528B1 (en) * 1991-01-31 2002-07-23 The University Court Of The University Of Glasgow Herpes simplex virus-1 deletion variants and vaccines thereof
US20030185855A1 (en) * 1994-07-29 2003-10-02 Christopher Maurice Preston HSV viral vector

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6423528B1 (en) * 1991-01-31 2002-07-23 The University Court Of The University Of Glasgow Herpes simplex virus-1 deletion variants and vaccines thereof
US20030185855A1 (en) * 1994-07-29 2003-10-02 Christopher Maurice Preston HSV viral vector

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BURTON EDWARD A ET AL: "Multiple applications for replication-defective herpes simplex virus vectors", STEM CELLS (MIAMISBURG), vol. 19, no. 5, 2001, pages 358 - 377, XP002337150, ISSN: 1066-5099 *
KRISKY D M ET AL: "DEVELOPMENT OF HERPES SIMPLEX VIRUS REPLICATION-DEFECTIVE MULTIGENEVECTORS FOR COMBINATION GENE THERAPY APPLICATIONS", GENE THERAPY, MACMILLAN PRESS LTD., BASINGSTOKE, GB, vol. 5, no. 11, November 1998 (1998-11-01), pages 1517 - 1530, XP000943836, ISSN: 0969-7128 *
MARCONI P ET AL: "Replication-defective Herpes Simplex Virus vectors for gene transfer in vivo", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 93, no. 21, 15 October 1996 (1996-10-15), pages 11319 - 11320, XP000650685, ISSN: 0027-8424 *
MURPHY CYNTHIA G ET AL: "Vaccine protection against simian immunodeficiency virus by recombinant strains of herpes simplex virus", JOURNAL OF VIROLOGY, vol. 74, no. 17, September 2000 (2000-09-01), pages 7745 - 7754, XP002336290, ISSN: 0022-538X *

Also Published As

Publication number Publication date
GB0406389D0 (en) 2004-04-21
WO2005092374A2 (fr) 2005-10-06

Similar Documents

Publication Publication Date Title
WO2005092374A3 (fr) Virus d'herpes simplex recombinant et leurs utilisations
WO2009012487A3 (fr) Pseudo-particules virales du virus chimère de la varicelle et du zona
PT1651666E (pt) Vacinas de citomegalovírus à base de alfavírus
EP1270016A4 (fr) Vaccin contre le virus du sida, contenant un vecteur du virus de sendai
WO2007008780A3 (fr) Compositions et procedes permettant d'eliciter une reponse immune a des mutants d'echappement de therapies ciblees
WO2004020643A3 (fr) Lyse bacterienne regulee destinee a l'administration d'un vecteur vaccinal genetique et a la liberation d'un antigene
DE60234375D1 (de) VERPACKUNG VON IMMUNSTIMULIERENDEM CpG IN VIRUSÄHNLICHEN PARTIKELN: HERSTELLUNGSVERFAHREN UND VERWENDUNG
EA200701128A1 (ru) Рекомбинантные штаммы bcg, обладающие повышенной способностью к высвобождению из эндосомы
WO2011143650A3 (fr) Vecteurs hcmv et rhcmv recombinants et utilisations de ceux-ci
WO2007024941A3 (fr) Vaccin polyvalent
WO2007008918A3 (fr) Vaccins de virus comprenant des proteines immunomodulatrices reliees a une enveloppe, et methode d'utilisation associee
WO2007052059A3 (fr) Modification de l'equilibre th1/th2 dans des vaccins antigrippaux sous-unitaires avec adjuvants
WO2011106607A3 (fr) Vaccins à virus fractionné pour les herpesvirus et procédés d'utilisation
AU2003246373A1 (en) Recombinant measles viruses expressing epitopes pf antigens of rna viruses and use of the recombinant viruses for the preparation of vaccine compositions
WO2004004761A3 (fr) Particule virale d'adjuvant
HK1076835A1 (en) Expression of genes in modified vaccinia virus ankara by using the cowpox ati promoter
WO2003023040A3 (fr) Mutants du virus de la vaccine obtenus par inactivation de mva-e3l et leur utilisation
WO2005077048A3 (fr) Immunomodulation par le biais de la regulation de l'expression du gene minor dans des cellules dendritiques immunes
WO2011057254A3 (fr) Vaccins à base de vecteur adénoviral simien
WO2007066188A3 (fr) Vaccins marqués contre le virus de la diarrhée virale bovine
WO2007059256A3 (fr) Bactéries pro-apoptotiques et compositions pour l'administration et l'expression d'antigènes
ATE494377T1 (de) Vakzine gegen ipnv die aus hefezellen isoliert werden
EP1427443A4 (fr) Vaccin mettant en oeuvre des proteines e du virus du papillome administrees par vecteur viral
ATE453708T1 (de) Impfstoff gegen west nile virus
WO2003077859A3 (fr) Procede visant a induire une reponse immunitaire renforcee contre le vih

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase